Combination IL-2 immunoconjugate therapy

Abstract

The present invention provides combinations of (a) an immunoconjugate comprising a first antibody engineered to have reduced effector function and an effector moiety, and (b) a second antibody engineered to have increased effector function, for use in treating a disease in an individual in need thereof. Further provided are pharmaceutical compositions comprising the combinations, and methods of using them.

The invention claimed is: 
     
       1. A method of treating a carcinoembryonic antigen (CEA)-expressing or Fibroblast Activation Protein (FAP) expressing cancer in an individual comprising administering to the individual a combination of:
 (a) an immunoconjugate comprising:
 (i) a first full-length IgG antibody which specifically binds to a CEA antigen or a FAP antigen, wherein the first full-length IgG antibody comprises a human IgG Fc region and is engineered to have reduced effector function compared to a corresponding non-engineered antibody and comprises in the heavy chain one or more amino acid substitutions selected from the group consisting of S228P, E233P, L234A, L235A, L235E, N297A, N297D, P331 S, and P329G according to EU numbering, and 
 (ii) a mutant interleukin-2 (IL-2) effector moiety, wherein the mutant IL-2 effector moiety is human IL-2 comprising the amino acid substitutions F42A, Y45A, and L72G according to the amino acid residue positions of SEQ ID NO:1, and 
 
 (b) a second full-length IgG antibody which specifically binds to an antigen selected from the group consisting of CD20 antigen, Epidermal Growth Factor Receptor (EGFR) antigen, HER2 antigen, HER3 antigen, Insulin-like Growth Factor 1 Receptor (IGF-1R) antigen, Carcinoembryonic Antigen (CEA) antigen, c-Met antigen, CUB domain-containing protein-1 (CDCP1) antigen, and Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP) antigen, wherein the second full-length IgG antibody comprises a human IgG Fc region and is engineered to have increased effector function compared to a corresponding non-engineered antibody and comprises (i) one or more amino acid substitutions at positions 298, 333, and/or 334 of the Fc region according to EU numbering or (ii) an increased proportion of non-fucosylated oligosaccharides in the Fc region as compared to a corresponding non-engineered antibody, in a therapeutically effective amount. 
 
     
     
       2. The method of  claim 1 , wherein the first antibody is an IgG 1  antibody. 
     
     
       3. The method of  claim 1 , wherein the mutant IL-2 effector moiety shares an amino- or carboxy-terminal peptide bond with the first antibody. 
     
     
       4. The method of  claim 1 , wherein the first antibody is engineered to have reduced binding to human FcγRIIIa. 
     
     
       5. The method of  claim 1 , wherein the first antibody comprises an amino acid substitution at position P329 in the immunoglobulin heavy chains according to EU numbering. 
     
     
       6. The method of  claim 1 , wherein the first antibody comprises the amino acid substitutions L234A, L235A and P329G in the immunoglobulin heavy chains according to EU numbering. 
     
     
       7. The method of  claim 1 , wherein the immunoconjugate consists essentially of the mutant IL-2 effector moiety and the first full-length IgG antibody, wherein the mutant IL-2 effector moiety is fused at its amino-terminal amino acid to the carboxy-terminus of one of the heavy chains of the first full-length IgG antibody, optionally through a peptide linker. 
     
     
       8. The method of  claim 1 , wherein the second antibody is an IgG 1  antibody. 
     
     
       9. The method of  claim 1 , wherein the effector function is selected from the group of binding to an activating Fc receptor, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and cytokine secretion. 
     
     
       10. The method of  claim 1 , wherein the effector function is binding to an activating Fc receptor and/or ADCC. 
     
     
       11. The method of  claim 1 , wherein the individual is a mammal, particularly a human. 
     
     
       12. The method of  claim 1 , wherein the first full-length IgG antibody comprises the heavy chain variable region sequence of SEQ ID NO: 114 and the light chain variable region sequence of SEQ ID NO: 115. 
     
     
       13. The method of  claim 1 , wherein the first full-length IgG antibody comprises:
 (a) the heavy chain variable region sequence of SEQ ID NO: 12 and the light chain variable region sequence of SEQ ID NO: 11; 
 (b) the heavy chain variable region sequence of SEQ ID NO: 17 and the light chain variable region sequence of SEQ ID NO: 16; 
 (c) the heavy chain variable region sequence of SEQ ID NO: 47 and the light chain variable region sequence of SEQ ID NO: 46; 
 (d) the heavy chain variable region sequence of SEQ ID NO: 63 and the light chain variable region sequence of SEQ ID NO: 62; or 
 (e) the heavy chain variable region sequence of SEQ ID NO: 67 and the light chain variable region sequence of SEQ ID NO: 66. 
 
     
     
       14. The method of  claim 1 , wherein the mutant IL-2 additionally comprises an amino acid mutation at a position corresponding to position 3 according to the amino acid residue positions of SEQ ID NO:1, which eliminates the O-glycosylation site of IL-2. 
     
     
       15. The method of  claim 14 , wherein the additional amino acid mutation is an amino acid substitution replacing a threonine residue with an alanine residue. 
     
     
       16. The method of  claim 1 , wherein the mutant IL-2 comprises the sequence of SEQ ID NO: 2. 
     
     
       17. The method of  claim 1 , wherein at least about 50% of the N-linked oligosaccharides in the Fc region of the second full-length IgG antibody are non-fucosylated. 
     
     
       18. The method of  claim 1 , wherein the second full-length IgG antibody comprises
 (i) a heavy chain variable domain comprising a complementary determining region (CDR) 1 of SEQ ID NO: 96, a CDR2 of SEQ ID NO: 97, and a CDR3 of SEQ ID NO: 98, and 
 (ii) a light chain variable domain comprising a CDR1 of SEQ ID NO: 99, a CDR2 of SEQ ID NO: 100, and a CDR3 of SEQ ID NO: 101. 
 
     
     
       19. The method of  claim 1 , wherein the cancer is selected from the group consisting of lung cancer, colorectal cancer, renal cancer, and head and neck cancer. 
     
     
       20. A method of stimulating effector cell function in an individual having a carcinoembryonic antigen (CEA)-expressing or Fibroblast Activation Protein (FAP) expressing cancer, comprising administering to the individual a combination of
 (a) an immunoconjugate comprising:
 (i) a first full-length IgG antibody which specifically binds to a CEA antigen or a FAP antigen, wherein the first full-length IgG antibody comprises a human IgG Fc region and is engineered to have reduced effector function compared to a corresponding non-engineered antibody and comprises in the heavy chain one or more amino acid substitutions selected from the group consisting of S228P, E233P, L234A, L235A, L235E, N297A, N297D, P331 S, and P329G according to EU numbering, and 
 (ii) a mutant interleukin-2 (IL-2) effector moiety, wherein the mutant IL-2 effector is human IL-2 comprising the amino acid substitutions F42A, Y45A, and L72G according to the amino acid residue positions of SEQ ID NO:1, and 
 
 (b) a second full-length IgG antibody which specifically binds to an antigen selected from the group consisting of CD20 antigen, Epidermal Growth Factor Receptor (EGFR) antigen, HER2 antigen, HER3 antigen, Insulin-like Growth Factor 1 Receptor (IGF-1R) antigen, Carcinoembryonic Antigen (CEA) antigen, c-Met antigen, CUB domain-containing protein-1 (CDCP1) antigen, and Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP) antigen, wherein the second full-length IgG antibody comprises a human IgG Fc region and is engineered to have increased effector function compared to a corresponding non-engineered antibody and comprises (i) one or more amino acid substitutions at positions 298, 333, and/or 334 of the Fc region according to EU numbering or (ii) an increased proportion of non-fucosylated oligosaccharides in the Fc region as compared to a corresponding non-engineered antibody, in an amount effective to stimulate effector cell function.